<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="6801">Metformin</z:chebi> and <z:chebi fb="0" ids="35664">statins</z:chebi> have shown promise for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> prevention </plain></SENT>
<SENT sid="1" pm="."><plain>This study assessed whether the effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> on <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> (PCa) incidence varied by <z:chebi fb="0" ids="35664">statin</z:chebi> use among type 2 diabetic patients </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: The study cohort consisted of 5,042 type 2 diabetic male patients seen in the Veteran Administration Health Care System who were without prior <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and were prescribed with <z:chebi fb="0" ids="6801">metformin</z:chebi> or <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> as the exclusive hypoglycemic medication between fiscal years 1999 and 2005 </plain></SENT>
<SENT sid="3" pm="."><plain>Cox proportional hazards analyses were conducted to assess the differential hazard ratio (HR) of PCa due to <z:chebi fb="0" ids="6801">metformin</z:chebi> by <z:chebi fb="0" ids="35664">statin</z:chebi> use versus <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> use, where propensity scores of <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="35664">statin</z:chebi> use were adjusted to account for imbalances in baseline covariates across medication groups </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Mean follow-up was 5 years, and 7.5% had a PCa diagnosis </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="35664">Statin</z:chebi> use modified the effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> on PCa incidence (P &lt; 0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> was associated with a significantly reduced PCa incidence among patients on <z:chebi fb="0" ids="35664">statins</z:chebi> (HR 0.69 [95% CI 0.50-0.92]; 17 cases/533 metformin users vs. 135 cases/2,404 sulfonylureas users) and an increased PCa incidence among patients not on <z:chebi fb="0" ids="35664">statins</z:chebi> (HR 2.15 [1.83-2.52]; 22 cases/175 metformin users vs. 186 cases/1,930 sulfonylureas users) </plain></SENT>
<SENT sid="7" pm="."><plain>The HR of PCa incidence for those taking <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="35664">statins</z:chebi> versus those taking neither medication was 0.32 (0.25-0.42) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Among men with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, PCa incidence among <z:chebi fb="0" ids="6801">metformin</z:chebi> users varied by their <z:chebi fb="0" ids="35664">statin</z:chebi> use </plain></SENT>
<SENT sid="9" pm="."><plain>The potential beneficial influence on PCa by combination use of <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="35664">statin</z:chebi> may be due to synergistic effects </plain></SENT>
</text></document>